Results 81 to 90 of about 1,015,959 (268)

EDNRB‐dependent endothelin signaling reduces proliferation and promotes proneural‐to‐mesenchymal transition in gliomas

Molecular Oncology, EarlyView.
Glioma cells mainly express the endothelin receptor EDNRB, while EDNRA is restricted to a perivascular tumor subpopulation. Endothelin signaling reduces glioma cell proliferation while promoting migration and a proneural‐to‐mesenchymal transition associated with poor prognosis. This pathway activates Ca2+, K+, ERK, and STAT3 signalings and is regulated
Donovan Pineau, Leonor Garcia, Hugo Arnold, Antonija Hanžek, Maialen Arrieta, Laurent R Gauthier, Christine Granotier‐Beckers, François D Boussin, Amaury Herbet, Marie Hautière, Valentin Asei‐Ceschino, Clémentin Jacques, Laura Brard, Thomas Harnois, Valérie Coronas, Bruno Constantin, Aurélien Chatelier, Jean Chemin, Serge Urbach, Martial Seveno, Szimonetta Hideg, Chantal Ripoll, Kasandra Aguilar‐Cázarez, Min Zheng, Guo‐Hao Huang, Sheng‐Qing Lv, Lei Zhang, Philippe Rondard, Laurent Prezeau, Jean‐Philippe Pin, Hugues Duffau, Luc Bauchet, Valérie Rigau, Franck Denat, Charles Truillet, Didier Boquet, Jean‐Philippe Hugnot   +36 more
wiley   +1 more source

The substance P and neurokinin-1 receptor system in human thyroid cancer: an immunohistochemical study

European Journal of Histochemistry, 2020
To develop a new therapeutic strategy against thyroid cancer (TC), the expression of both substance P (SP) and neurokinin-1 receptor (NK-1R) must be demonstrated in TC cells.
Inmaculada Isorna, Francisco Esteban, Juan Solanellas, Rafael Coveñas, Miguel Muñoz   +4 more
doaj   +1 more source

Engineered extracellular vesicles enriched with the miR‐214/199a cluster enhance the efficacy of chemotherapy in ovarian cancer

Molecular Oncology, EarlyView.
Loss of the miR‐214/199a cluster is associated with recurrence in ovarian cancer. Engineered small extracellular vesicles (m214‐sEVs) elevate miR‐214‐3p/miR‐199a‐5p in tumor cells, suppress β‐catenin, TLR4, and YKT6 signaling, reprogram tumor‐derived sEV cargo, reduce chemoresistance and migration, and enhance carboplatin efficacy and survival in ...
Weida Wang, Ayesha Alvero, Yi Qin, Mingjin Wang, Alexandra Fox, Yanfeng Li, Michael Millman, Amy Kemper, Gil Mor, Xian Shuang Liu, Michael Chopp, Zheng Gang Zhang, Yi Zhang   +12 more
wiley   +1 more source

suppression from hadron-nucleus to nucleus-nucleus collisions

Nuclear Physics B, 1990
Abstract We explore the combined role of inelastic final-state scattering with nucleons and comoving secondary particles in the suppression of J ψ production for hadron-nucleus and nucleus-nucleus collisions, as functions of target mass, beam energy, and transverse energy.
S. Gavin, R. Vogt
openaire   +1 more source

Keratin 19 as a prognostic marker and contributing factor of metastasis and chemoresistance in high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Keratin 19 (KRT19) is overexpressed in high‐grade serous ovarian cancer with high levels of Kallikrein‐related peptidases (KLK) 4–7 and is associated with poor survival. In vivo analyses demonstrate that elevated KRT19 increases peritoneal tumour burden.
Sophia Bielesch, Isabel Vogel, Sina Nokodian, Johanna Moeller, Antonia Blechschmidt, Vicky Hecht, Vanessa Kuentzel, Katharina Thiedig, Melissa Schwab, Oliver Schilling, Holger Bronger, Marion Kiechle, Viktor Magdolen, Tobias Dreyer   +13 more
wiley   +1 more source

Differential expression of cancer‐related genes supports prediction of poor response to first‐line treatments in T‐ALL pediatric patients with high minimal residual disease

Molecular Oncology, EarlyView.
In the present work, we have identified a transcriptional signature based on the differential expression of six genes (BCL2&MAST4, HSH2D&LAT2, METRN&PITPNM2) that would facilitate the early detection of T‐cell acute lymphoblastic leukemia (T‐ALL) patients prone to a poor treatment response and could be implemented at diagnosis, along with other risk ...
Antonio Lahera, Laura Vela‐Martín, Pablo Fernández‐Navarro, José Luis López‐Lorenzo, Javier Cornago, Pilar Llamas, Eduardo Pérez‐Gómez, José Luis Marín‐Rubio, Manuel Fresno, Javier Santos, José Fernández‐Piqueras, María Villa‐Morales   +11 more
wiley   +1 more source

CCDC80 suppresses high‐grade serous ovarian cancer migration via negative regulation of B7‐H3

Molecular Oncology, EarlyView.
PAX8 is a lineage‐specific master regulator of transcription in high‐grade serous ovarian cancer (HGSC) progression. We show for the first time that PAX8 facilitates proliferation and metastasis by repressing the cell autonomous tumor suppressor CCDC80 and inducing B7‐H3 expression.
Aya Saleh, Nitzan Medina‐Itzhaki, Milena Chekov, Eden Gal‐Swisa, Roba Gabesh‐Wahabi, Inbar Savyon, Inna Naroditsky, Hilary A. Kenny, Basem Fares, Lina Korsensky, Einav Girsh, Liron Berger, Ruth Perets   +12 more
wiley   +1 more source

Quarkonium measurements in nucleus–nucleus collisions with ALICE

Nuclear Physics A, 2019
Quarkonia, i.e. bound states of $b\bar{b}$ and $c\bar{c}$ quarks, are powerful observables to study the properties of nuclear matter under extreme conditions. The formation of a Quark-Gluon Plasma (QGP), which is predicted by lattice QCD calculations at high temperatures as reached at LHC energies, has a strong influence on the production and behavior ...
Dillenseger, Pascal and Acharya, S, Acosta, F. T, Adamova, D, Adolfsson, J, Aggarwal, M. M, Rinella, G. Aglieri and Agnello, M, Agrawal, N, Ahammed, Z, Ahn, S. U, Aiola, S, Akindinov, A, Al-Turany, M, Alam, S. N, Albuquerque, D. S. D, Aleksandrov, D, Alessandro, B, Alfaro Molina, R, Ali, Y, Alici, A, Alkin, A, Alme, J, Alt, T, Altenkamper, L, Altsybeev, I and Anaam, M. N, Andrei, C, Andreou, D, Andrews, H. A, Andronic, A, Angeletti, M, Anguelov, V and Anson, C, Anticic, T, Antinori, F, Antonioli, P, Anwar, R, Apadula, N, Aphecetche, L, Appelshaeuser, H, Arcelli, S, Arnaldi, R, Arnold, O. W, Arratia, M, Arsene, I. C, Arslandok, M, Augustinus, A, Averbeck, R, Azmi, M. D, Badala, A, Baek, Y. W, Bagnasco, S, Bailhache, R, Bala, R, Baldisseri, A, Ball, M, Baral, R. C, Barbano, A. M, Barbera, R, Barile, F, Barioglio, L, Barnafoldi, G. G, Barnby, L. S, Barret, V and Bartalini, P, Barth, K, Bartsch, E, Bastid, N, Basu, S, Batigne, G, Batyunya, B, Batzing, P. C, Bazo Alba, J. L, Bearden, I. G, Beck, H, Bedda, C, Behera, N. K, Belikov, I and Bellini, F, Bello Martinez, H, Bellwied, R, Beltran, L. G. E, Belyaev, V and Bencedi, G, Beole, S, Bercuci, A, Berdnikov, Y, Berenyi, D, Bertens, R. A, Berzano, D, Betev, L, Bhaduri, P. P, Bhasin, A, Bhat, I. R, Bhatt, H, Bhattacharjee, B, Bhom, J, Bianchi, A, Bianchi, L, Bianchi, N, Bielcik, J, Bielcikova, J, Bilandzic, A, Biro, G, Biswas, R, Biswas, S, Blair, J. T, Blau, D, Blume, C, Boca, G, Bock, F, Bogdanov, A, Boldizsar, L, Bombara, M, Bonomi, G, Bonora, M, Borel, H, Borissov, A, Borri, M, Botta, E, Bourjau, C, Bratrud, L, Braun-Munzinger, P, Bregant, M, Broker, T. A, Broz, M, Brucken, E. J, Bruna, E, Bruno, G. E, Budnikov, D, Buesching, H, Bufalino, S, Buhler, P, Buncic, P, Busch, O, Buthelezi, Z, Butt, J. B, Buxton, J. T, Cabala, J, Caffarri, D, Caines, H, Caliva, A, Calvo Villar, E, Camacho, R. S, Camerini, P, Capon, A. A, Carena, F, Carena, W, Carnesecchi, F, Castellanos, J. Castillo and Castro, A. J, Casula, E. A. R, Ceballos Sanchez, C, Chandra, S, Chang, B, Chang, W, Chapeland, S, Chartier, M, Chattopadhyay, S, Chauvin, A, Cheshkov, C, Cheynis, B, Barroso, V. Chibante and Chinellato, D. D, Cho, S, Chochula, P, Chowdhury, T, Christakoglou, P, Christensen, C. H, Christiansen, P, Chujo, T, Chung, S. U, Cicalo, C, Cifarelli, L, Cindolo, F, Cleymans, J, Colamaria, F, Colella, D, Collu, A, Colocci, M, Concas, M, Balbastre, G. Conesa and del Valle, Z. Conesa and Contreras, J. G, Cormier, T. M, Morales, Y. Corrales and Cortese, P, Cosentino, M. R, De Caro, A, De Gruttola, D, De Pasquale, S, Fantoni, A, Fernandez Tellez, A, Ferretti, A, Giubilato, P, Gulbrandsen, K, Hills, C, Kobdaj, C, Loncar, P, Lunardon, M, Moretto, S, Natal da Luz, H, Nielsen, B. S, Noris, J. C. C, Ogino, M, Paul, B, Scapparone, E, Scarlassara, F, Sefcik, M, Sevcenco, A, Sharma, N, Soramel, F, Suaide, A. A. P, Suleymanov, M, Terrevoli, C, Virgili, T, Volpe, G, Yalcin, S, Zhou, Y   +230 more
openaire   +15 more sources

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Heterozygous loss‐of‐function alleles associate the conserved 3′‐5′ exoribonuclease EXOSC10 with hypersensitivity to the anticancer drug 5‐fluorouracil

Molecular Oncology, EarlyView.
EXOSC10, an essential nuclear RNA exosome‐associated 3′‐5′ exoribonuclease, is inhibited by the anticancer drug 5‐fluorouracil (5‐FU), and EXOSC10 depletion increases 5‐FU sensitivity. The colon‐cancer variant EXOSC10S402T, located in a proteolysis motif, is stable and nuclear but nonfunctional in vivo.
Radhika Sain, Yann Le Page, Frédéric Percevault, Emmanuelle Becker, Luc Negroni, Almudena Fernandez, Marta Cantero, Diego Muñoz‐Santos, Lluís Montoliu, Cyrille Garnier, Michael Primig   +10 more
wiley   +1 more source